Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders

Y Chen, J Xu, Y Chen - Nutrients, 2021 - mdpi.com
Emerging evidence indicates that gut microbiota is important in the regulation of brain
activity and cognitive functions. Microbes mediate communication among the metabolic …

Comprehensive review on Alzheimer's disease: causes and treatment

Z Breijyeh, R Karaman - Molecules, 2020 - mdpi.com
Alzheimer's disease (AD) is a disorder that causes degeneration of the cells in the brain and
it is the main cause of dementia, which is characterized by a decline in thinking and …

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies

J Zhang, Y Zhang, J Wang, Y Xia, J Zhang… - Signal transduction and …, 2024 - nature.com
Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

Pushing the frontiers: tools for monitoring neurotransmitters and neuromodulators

Z Wu, D Lin, Y Li - Nature Reviews Neuroscience, 2022 - nature.com
Neurotransmitters and neuromodulators have a wide range of key roles throughout the
nervous system. However, their dynamics in both health and disease have been challenging …

Pathological mechanisms and therapeutic strategies for Alzheimer's disease

Y Ju, KY Tam - Neural regeneration research, 2022 - journals.lww.com
Alzheimer's disease is a rather complex neurodegenerative disease, which is attributed to a
combination of multiple factors. Among the many pathological pathways, synaptic …

Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia

E Connell, G Le Gall, MG Pontifex, S Sami… - Molecular …, 2022 - Springer
A consequence of our progressively ageing global population is the increasing prevalence
of worldwide age-related cognitive decline and dementia. In the absence of effective …

History and progress of hypotheses and clinical trials for Alzheimer's disease

PP Liu, Y Xie, XY Meng, JS Kang - Signal transduction and targeted …, 2019 - nature.com
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …

Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease

S Khan, KH Barve, MS Kumar - Current neuropharmacology, 2020 - ingentaconnect.com
Background: The only conclusive way to diagnose Alzheimer's is to carry out brain autopsy
of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other …

Neuroprotective effect of SGLT2 inhibitors

A Pawlos, M Broncel, E Woźniak, P Gorzelak-Pabiś - Molecules, 2021 - mdpi.com
Patients with diabetes are at higher risk of cardiovascular diseases and cognitive
impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin …

[HTML][HTML] Kaempferol, a potential neuroprotective agent in neurodegenerative diseases: From chemistry to medicine

S Jin, L Zhang, L Wang - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Neurodegenerative diseases (NDDs) encompass a range of conditions that involve
progressive deterioration and dysfunction of the nervous system. Some of the common …